Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Clin Infect Dis. 2010 Nov 1;51(9):1070-2. doi: 10.1086/656585.

    A 4‐site, single‐visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients.

    Source

    Queen Saovabha Memorial Institute, Thai Red Cross Society, World Health Organization Collaborating Center for Research in Rabies Pathogenesis and Treatment, Bangkok, Thailand. sprapimporn@gmail.com

    Abstract

    We previously demonstrated that 4‐site, intradermal, single‐visit rabies booster vaccination provides immunogenicity greater than that provided by the standard 2‐booster, 2‐visit regimen. The regimen has been routinely used in 5116 patients since 1998 without any treatment failure. It is not only effective but also saves vaccine costs and transportation expenses and improves compliance.

    PMID:
    20887204
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk